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CFR: Not Scheduled (11/2021) 
CAS#    1048973-67-6 
Synonyms: Cyclohexylmethyl MDA-19, CHM-MDA-19     
Source:   Indianapolis-Marion County Forensic Services Agency 
Appearance:   Plant-Like Material 
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2. CHEMICAL AND PHYSICAL DATA 










Base C22H23N3O2 361.4 361 362.1863 
 
3. BRIEF DESCRIPTION 
BZO-CHMOXIZID is classified as a synthetic cannabinoid. Synthetic cannabinoids have 
been reported to cause psychoactive effects similar to delta-9-tetrahydrocannabinol (THC). 
Synthetic cannabinoids have caused adverse events, including deaths, as described in the 
literature. Closely related analogue BZO-HEXOXIZID (MDA 19) was synthesized and studied 
in the late 2000’s by scientists at the University of Texas M. D. Anderson Cancer Center.1,2,3 
BZO-HEXOXIZID is reported to be a potent and selective cannabinoid receptor 2 (CB2) agonist. 
Several closely related analogues make up this new generation of synthetic cannabinoids, some 
of which have been studied and reported.3,4 Scientists at Cayman Chemical and the CFSRE 
developed a new naming convention for this subclass, calling these new drugs the “OXIZIDs”.5 
OXIZID represents the core/linker region of this new synthetic cannabinoid structure. The 
OXIZID subclass recently emerged among the recreation drug supply internationally, seemingly 
as replacements after a synthetic cannabinoid class-wide ban implemented by China in July 2021 
which included most traditional indole and indazole structural scaffolds.6 To date, multiple 
OXIZID analogues have been identified worldwide, most of which are unstudied with 
pharmacological and human effects undetermined. Currently, no analogues of the OXIZID 
subclass are scheduled substances in the United States.  
 
BZO-HEXOXIZID BZO-POXIZID 5F-BZO-POXIZID BZO-CHMOXIZID 
      
  
(Z)-N’-(1-HEXyl-2-OXoIndolin-    
3-ylidene)BenZOhydraZIDe 








Name: BZO-HEXOXIZID Name: BZO-POXIZID Name: 5F-BZO-POXIZID Name: BZO-CHMOXIZID 
Synonyms: MDA-19,            
MDA19, MDA 19 
Synonyms: 5C-MDA-19,              
MDA-19 pentyl analogue 
Synonyms: 5F-MDA-19,             
MDA-19 5-fluoropentyl analogue 
Synonyms: CHM-MDA-19,           
Cyclohexylmethyl MDA-19 
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5. QUALITATIVE DATA 
5.1 GAS CHROMATOGRAPHY MASS SPECTROMETRY (GC-MS) 
Testing Performed At: The Center for Forensic Science Research and Education at the 
Fredric Rieders Family Foundation (Willow Grove, PA) 
Sample Preparation:  Dilution in methanol (Indianapolis-Marion County Forensic 
Services Agency) 
Instrument:   Agilent 5975 Series GC/MSD System 
Column:   Agilent J&W DB-1 (12 m x 200 µm x 0.33 µm) 
Carrier Gas:   Helium (Flow: 1.46 mL/min) 
Temperatures:  Injection Port: 265 °C 
    Transfer Line: 300 °C 
    MS Source: 230 °C 
    MS Quad: 150 °C 
    Oven Program: 50 °C for 0 min, 30 °C/min to 340 °C for 2.3 min 
Injection Parameters: Injection Type: Splitless  
    Injection Volume: 1 µL 
MS Parameters:  Mass Scan Range: 40-550 m/z 
    Threshold: 250 
Retention Time:  9.13 min 
Standard Comparison: Reference material for BZO-CHMOXIZID (Batch: 0628347-1) 
was purchased from Cayman Chemical (Ann Arbor, MI, USA). 
Analysis of this standard resulted in positive identification of the 
analyte in the exhibit as BZO-CHMOXIZID based on retention 









Additional peaks in chromatogram: not a controlled substance (2.94 min)                                
and internal standards (3.08 and 5.72 mins) 
 
EI (70 eV) Mass Spectrum: BZO-CHMOXIZID 
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5.2 LIQUID CHROMATOGRAPHY QUADRUPOLE TIME OF FLIGHT MASS 
SPECTROMETRY (LC-QTOF) 
Testing Performed At: The Center for Forensic Science Research and Education at the 
Fredric Rieders Family Foundation (Willow Grove, PA) 
Sample Preparation:  Dilution in methanol (Indianapolis-Marion County Forensic 
Services Agency) followed by 1:100 dilution of GC-MS sample in 
mobile phase (CFSRE) 
Instrument:   Sciex TripleTOF® 5600+, Shimadzu Nexera XR UHPLC 
Column:   Phenomenex® Kinetex C18 (50 mm x 3.0 mm, 2.6 µm) 
Mobile Phase:  A: Ammonium formate (10 mM, pH 3.0) 
    B: Methanol/acetonitrile (50:50) 
    Flow rate: 0.4 mL/min 
Gradient:   Initial: 95A:5B; 5A:95B over 13 min; 95A:5B at 15.5 min 
Temperatures:  Autosampler: 15 °C 
    Column Oven: 30 °C 
    Source Heater: 600 °C 
Injection Parameters: Injection Volume: 10 µL 
QTOF Parameters:  TOF MS Scan Range: 100-510 Da 
    Precursor Isolation: SWATH® acquisition (27 windows) 
    Fragmentation: Collison Energy Spread (35±15 eV) 
    MS/MS Scan Range: 50-510 Da 
Retention Time:  10.61 min 
Standard Comparison: Reference material for BZO-CHMOXIZID (Batch: 0628347-1) 
was purchased from Cayman Chemical (Ann Arbor, MI, USA). 
Analysis of this standard resulted in positive identification of the 
analyte in the exhibit as BZO-CHMOXIZID based on retention 
time (10.62 min) and mass spectral data. 
(https://www.caymanchem.com/product/34956/bzo-chmoxizid) 




Additional peaks in chromatogram: internal standards (4.88 and 7.24 mins) 
 
TOF MS Spectra: BZO-CHMOXIZID 
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